2026-04-14T04:37:27Zhttps://recercat.cat/oai/request
oai:recercat.cat:2445/1958052025-11-20T15:52:17Zcom_2072_1057col_2072_478798col_2072_478917
RECERCAT author Harrington, Kevin J. author Burtness, Barbara author Greil, Richard author Soulières, Denis author Tahara, Makoto author Castro, Gilberto de author Psyrri, Amanda author Braña, Irene author Basté, Neus author Neupane, Prakash author Bratland, Åse author Fuereder, Thorsten author Hughes, Brett G.M. author Mesía Nin, Ricard author Ngamphaiboon, Nuttapong author Rordorf, Tamara author Ishak, Wan Zamaniah Wan author Lin, Jiaxin author Gumuscu, Burak author Swaby, Ramona F. author Rischin, Danny 2023-03-22T15:59:46Z2023-04-11T05:10:31Z2022-10-112023-03-22T15:59:46Z Purpose: Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048. Post hoc analysis of long-term efficacy and progression-free survival on next-line therapy (PFS2) is presented. Methods: Patients were randomly assigned (1:1:1) to pembrolizumab, pembrolizumab-chemotherapy, or cetuximab-chemotherapy. Efficacy was evaluated in programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥ 20, CPS ≥ 1, and total populations, with no multiplicity or alpha adjustment. Results: The median study follow-up was 45.0 months (interquartile range, 41.0-49.2; n = 882). At data cutoff (February 18, 2020), overall survival improved with pembrolizumab in the PD-L1 CPS ≥ 20 (hazard ratio [HR], 0.61; 95% CI, 0.46 to 0.81) and CPS ≥ 1 populations (HR, 0.74; 95% CI, 0.61 to 0.89) and was noninferior in the total population (HR, 0.81; 95% CI, 0.68 to 0.97). Overall survival improved with pembrolizumab-chemotherapy in the PD-L1 CPS ≥ 20 (HR, 0.62; 95% CI, 0.46 to 0.84), CPS ≥ 1 (HR, 0.64; 95% CI, 0.53 to 0.78), and total (HR, 0.71; 95% CI, 0.59 to 0.85) populations. The objective response rate on second-course pembrolizumab was 27.3% (3 of 11). PFS2 improved with pembrolizumab in the PD-L1 CPS ≥ 20 (HR, 0.64; 95% CI, 0.48 to 0.84) and CPS ≥ 1 (HR, 0.79; 95% CI, 0.66 to 0.95) populations and with pembrolizumab-chemotherapy in the PD-L1 CPS ≥ 20 (HR, 0.64; 95% CI, 0.48 to 0.86), CPS ≥ 1 (HR, 0.66; 95% CI, 0.55 to 0.81), and total (HR, 0.73; 95% CI, 0.61 to 0.88) populations. PFS2 was similar after pembrolizumab and longer after pembrolizumab-chemotherapy on next-line taxanes and shorter after pembrolizumab and similar after pembrolizumab-chemotherapy on next-line nontaxanes. Conclusion: With a 4-year follow-up, first-line pembrolizumab and pembrolizumab-chemotherapy continued to demonstrate survival benefit versus cetuximab-chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma. Patients responded well to subsequent treatment after pembrolizumab-based therapy. (c) American Society of Clinical Oncology, 2022 info:eu-repo/semantics/openAccess Quimioteràpia Càncer de cap Càncer de coll Anticossos monoclonals Chemotherapy Head cancer Neck cancer Monoclonal antibodies Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion